Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/16999
Title: Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding
Authors: Torresi, Joseph;Richmond, Peter C;Heron, Leon G;Qiao, Ming;Marjason, Joanne;Starr-Spires, Linda;van der Vliet, Diane;Jin, Jing;Wartel, T Anh;Bouckenooghe, Alain
Issue Date: Oct-2017
Citation: Journal of Infectious Diseases 2017; 216(7): 834-841
Abstract: BACKGROUND: We assessed replication and excretion of the live attenuated tetravalent dengue vaccine (CYD-TDV) into biological fluids following vaccination in dengue-naive adults in Australia. METHODS: Vaccinal viremia/shedding was assessed in a subset of participants enrolled in a lot-to-lot consistency study; 95 participants received 3 subcutaneous doses of CYD-TDV from phase 2/3 lots of the vaccine, and 8 received placebo; doses were administered 6 months apart. Quantitative reverse-transcription polymerase chain reaction (qR-PCR) analysis was used to initially detect the yellow fever virus (YFV) core protein gene in the backbone of CYD-TDV in serum, saliva and urine, followed by serotype-specific qRT-PCR analysis of samples positive for YFV by qRT-PCR (lower limit of detection, 5.16 GEq/mL). RESULTS: YFV viremia was detected by qRT-PCR in 69.5% of participants (66 of 95) who received CYD-TDV, mainly 6-14 days after injection 1. The serotypes detected were serotype 4 (in 68.2% of participants [45 of 95]), serotype 3 (in 19.7% [13 of 95]), and serotype 1 (in 12.1% [8 of 95]); serotype 2 was not detected. None of the placebo recipients had vaccinal viremia/shedding. No participants had detectable viral shedding into saliva at levels above the lower limit of quantitation. Two participants had low-level viral shedding (serotype 3) in urine (5.47 and 5.77 GEq/mL). None of the participants with viremia or shedding experienced concomitant fever. CONCLUSIONS: Low-level vaccinal viremia may occur following vaccination with CYD-TDV, but this is not associated with any symptom or adverse event. CLINICAL TRIALS REGISTRATION: NCT01134263.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16999
DOI: 10.1093/infdis/jix314
ORCID: 0000-0002-8212-0887
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/28968794
Type: Journal Article
Subjects: Flavivirus
dengue
shedding
vaccine
viremia
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.